Quest PharmaTech Stock Forecast, Price & News

+0.01 (+6.25 %)
(As of 09/10/2021)
Today's Range
50-Day Range
52-Week Range
Volume93,204 shs
Average Volume54,867 shs
Market CapitalizationC$14.30 million
P/E Ratio0.17
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive QPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest PharmaTech and its competitors with MarketBeat's FREE daily newsletter.

About Quest PharmaTech

Quest PharmaTech Inc., a biopharmaceutical company, develops and commercializes antibody based immunotherapeutic products for cancer. Its lead product candidates are Mab AR 9.6 against truncated O-glycan on MUC16 for targeted cancer therapy applications; and Oregovomab, an anti-CA-125 antibody, which has completed Phase II clinical trial for the treatment of ovarian cancer. The company also develops combinatorial immunotherapeutic products for cancer by using monoclonal antibodies of the immunoglobulin G and E class in combination with chemotherapy/immune-adjuvant; and immunotherapy products for pancreatic cancer. In addition, it develops products by using proprietary transdermal delivery technologies for dermatology and wound healing applications; and skin penetrating active molecules for cosmetic and pharmaceutical use. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.


Brooklyn shotput phenom earns first national gold
Brooklyn shotput phenom earns first national gold
July 9, 2021 |
June 3, 2021 |
Quest PharmaTech Inc
Quest PharmaTech Inc
January 29, 2021 |
Quest PharmaTech Inc. (QPT.V)
Quest PharmaTech Inc. (QPT.V)
January 8, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.17 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Quest PharmaTech (CVE:QPT) Frequently Asked Questions

What stocks does MarketBeat like better than Quest PharmaTech?

Wall Street analysts have given Quest PharmaTech a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Quest PharmaTech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Quest PharmaTech's next earnings date?

Quest PharmaTech is scheduled to release its next quarterly earnings announcement on Thursday, September 23rd 2021.
View our earnings forecast for Quest PharmaTech

How has Quest PharmaTech's stock been impacted by COVID-19?

Quest PharmaTech's stock was trading at C$0.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, QPT shares have decreased by 22.7% and is now trading at C$0.09.
View which stocks have been most impacted by COVID-19

Who are Quest PharmaTech's key executives?

Quest PharmaTech's management team includes the following people:
  • Dr. Ragupathy Madiyalakan, CEO & Director
  • Mr. Pierre Vermette, Chief Financial Officer
  • Mr. Thomas Woo, VP of Product Devel.
  • Mr. Roger Andrews, Head of Investor Relations & Corp. Communications
  • Mr. Douglas C. Bachman, VP of Corp. Devel. (Age 67)

Who are some of Quest PharmaTech's key competitors?

What other stocks do shareholders of Quest PharmaTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest PharmaTech investors own include Indiva (NDVA), CME Group (CME) and (APHA).

What is Quest PharmaTech's stock symbol?

Quest PharmaTech trades on the Canadian Venture Exchange (CVE) under the ticker symbol "QPT."

How do I buy shares of Quest PharmaTech?

Shares of QPT and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Quest PharmaTech's stock price today?

One share of QPT stock can currently be purchased for approximately C$0.09.

How much money does Quest PharmaTech make?

Quest PharmaTech has a market capitalization of C$14.30 million and generates C$38,871.00 in revenue each year.

How many employees does Quest PharmaTech have?

Quest PharmaTech employs 147,000 workers across the globe.

What is Quest PharmaTech's official website?

The official website for Quest PharmaTech is

Where are Quest PharmaTech's headquarters?

Quest PharmaTech is headquartered at 8123 Roper Rd NW, EDMONTON, AB T6E 6S4, Canada.

How can I contact Quest PharmaTech?

Quest PharmaTech's mailing address is 8123 Roper Rd NW, EDMONTON, AB T6E 6S4, Canada. The company can be reached via phone at +1-780-4481400.

This page was last updated on 9/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.